Tomas Hornak (Tomáš Horňák)

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 10

Top Venues

Leukemia

American journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Daniela Zackova, Lukáš Semerád, Edgar Faber, Hana Klamová, Lukáš Stejskal, Petra Bělohlávková, Michal Karas, Eduard Cmunt, Olga Černá, Jiřina Procházková, Petra Čičátková, Anežka Kvetková, Tomas Hornak, Ivana Skoumalová, Dana Srbová, Cyril Salek, David Buffa, Jaroslava Voglová, Tomáš Jurček, Adam Folta, Ivana Ježíšková, Hana Žižková, Kateřina Machová Poláková, Tomáš Papajík, Pavel Žák, Pavel Jindra, Adam Svobodník, Radka Štěpánová, Jiří Mayer
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia 38 (4) (2024)
Tomas Hornak, Jiri Mayer, Petra Cicatkova, Lukas Semerad, Anezka Kvetkova, Hana Klamova, Edgar Faber, Petra Belohlavkova, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Dana Srbova, Hana Zizkova, Lucia Vrablova, Ivana Skoumalova, Jaroslava Voglova, Tereza Jurkova, Marika Chrapava, Tomas Jurcek, Ivana Jeziskova, Marie Jarosova, Katerina Machova Polakova, Tomas Papajik, Pavel Zak, Pavel Jindra, Daniela Zackova
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors. American journal of hematology (2024)
Daniela Zackova, Lukáš Semerád, Edgar Faber, Hana Klamová, Lukáš Stejskal, Petra Bělohlávková, Michal Karas, Eduard Cmunt, Olga Černá, Jiřina Procházková, Petra Čičátková, Anežka Kvetková, Tomas Hornak, Ivana Skoumalová, Dana Srbová, Cyril Salek, David Buffa, Jaroslava Voglová, Tomáš Jurček, Adam Folta, Ivana Ježíšková, Hana Žižková, Kateřina Machová Poláková, Tomáš Papajík, Pavel Žák, Pavel Jindra, Adam Svobodník, Radka Štěpánová, Jiří Mayer
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia 38 (4) (2024)
Daniela Zackova, Lukáš Semerád, Edgar Faber, Hana Klamová, Lukáš Stejskal, Petra Bělohlávková, Michal Karas, Eduard Cmunt, Olga Černá, Jiřina Procházková, Petra Čičátková, Anežka Kvetková, Tomas Hornak, Ivana Skoumalová, Dana Srbová, Cyril Salek, David Buffa, Jaroslava Voglová, Tomáš Jurček, Adam Folta, Ivana Ježíšková, Hana Žižková, Kateřina Machová Poláková, Tomáš Papajík, Pavel Žák, Pavel Jindra, Adam Svobodník, Radka Štěpánová, Jiří Mayer
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia 38 (4) (2024)
Tomas Hornak, Jiri Mayer, Petra Cicatkova, Lukas Semerad, Anezka Kvetkova, Hana Klamova, Edgar Faber, Petra Belohlavkova, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Dana Srbova, Hana Zizkova, Lucia Vrablova, Ivana Skoumalova, Jaroslava Voglova, Tereza Jurkova, Marika Chrapava, Tomas Jurcek, Ivana Jeziskova, Marie Jarosova, Katerina Machova Polakova, Tomas Papajik, Pavel Zak, Pavel Jindra, Daniela Zackova
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors. American journal of hematology 99 (4) (2024)
Daniela Zackova, Lukáš Semerád, Edgar Faber, Hana Klamová, Lukáš Stejskal, Petra Bělohlávková, Michal Karas, Eduard Cmunt, Olga Černá, Jiřina Procházková, Petra Čičátková, Anežka Kvetková, Tomas Hornak, Ivana Skoumalová, Dana Srbová, Cyril Salek, David Buffa, Jaroslava Voglová, Tomáš Jurček, Adam Folta, Ivana Ježíšková, Hana Žižková, Kateřina Machová Poláková, Tomáš Papajík, Pavel Žák, Pavel Jindra, Adam Svobodník, Radka Štěpánová, Jiří Mayer
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia (2024)
Daniela Zackova, Lukáš Semerád, Edgar Faber, Hana Klamová, Lukáš Stejskal, Petra Bělohlávková, Michal Karas, Eduard Cmunt, Olga Černá, Jiřina Procházková, Petra Čičátková, Anežka Kvetková, Tomas Hornak, Ivana Skoumalová, Dana Srbová, Cyril Salek, David Buffa, Jaroslava Voglová, Tomáš Jurček, Adam Folta, Ivana Ježíšková, Hana Žižková, Kateřina Machová Poláková, Tomáš Papajík, Pavel Žák, Pavel Jindra, Adam Svobodník, Radka Štěpánová, Jiří Mayer
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia 38 (4) (2024)
Daniela Zackova, Lukáš Semerád, Edgar Faber, Hana Klamová, Lukáš Stejskal, Petra Bělohlávková, Michal Karas, Eduard Cmunt, Olga Černá, Jiřina Procházková, Petra Čičátková, Anežka Kvetková, Tomas Hornak, Ivana Skoumalová, Dana Srbová, Cyril Salek, David Buffa, Jaroslava Voglová, Tomáš Jurček, Adam Folta, Ivana Ježíšková, Hana Žižková, Kateřina Machová Poláková, Tomáš Papajík, Pavel Žák, Pavel Jindra, Adam Svobodník, Radka Štěpánová, Jiří Mayer
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia 38 (4) (2024)
Tomas Hornak, Jiri Mayer, Petra Cicatkova, Lukas Semerad, Anezka Kvetkova, Hana Klamova, Edgar Faber, Petra Belohlavkova, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Dana Srbova, Hana Zizkova, Lucia Vrablova, Ivana Skoumalova, Jaroslava Voglova, Tereza Jurkova, Marika Chrapava, Tomas Jurcek, Ivana Jeziskova, Marie Jarosova, Katerina Machova Polakova, Tomas Papajik, Pavel Zak, Pavel Jindra, Daniela Zackova
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors. American journal of hematology 99 (4) (2024)
Tomas Hornak, Jiri Mayer, Petra Cicatkova, Lukas Semerad, Anezka Kvetkova, Hana Klamova, Edgar Faber, Petra Belohlavkova, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Dana Srbova, Hana Zizkova, Lucia Vrablova, Ivana Skoumalova, Jaroslava Voglova, Tereza Jurkova, Marika Chrapava, Tomas Jurcek, Ivana Jeziskova, Marie Jarosova, Katerina Machova Polakova, Tomas Papajik, Pavel Zak, Pavel Jindra, Daniela Zackova
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors. American journal of hematology 99 (4) (2024)

Tomas Hornak.css-eqlu8i{font-size:small;padding-left:4px;} (Tomáš Horňák)

Publication Activity (10 Years)

Top Topics

Top Venues

Tomas Hornak (Tomáš Horňák)